New hormonal composition and its use
AssigneeLaboratoire Theramex
InventorsJacques Paris, Jean-Louis Thomas
Life of this patent
Estimating the term…
Abstract
A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17β-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.
Claims17
Pharmaceutical hormone compositions characterised in that they are formed of a combined estrogen-progestative association intended for oral administration, and they make possible the simultaneous administration of an estrogenic compound at a dose ranging from 0.3 to 3 mg and a progestative compound derived from 19-norprogesterone at a dose ranging from 0.3 to 1.5 mg, in association or in admixture with one or more non-toxic, inert and pharmaceutically acceptable diluents.
Dependencies are inferred from the claim text.